- Enlivex Therapeutics Ltd. reported a **net loss of $1,868 thousand** or **$(0.08) per share** for the three months ended June 30, 2025, and a **net loss of $5,320 thousand** or **$(0.22) per share** for the six months ended June 30, 2025.  **[1596812_0001213900-25-082585_ea025461701ex99-1_enlivex.htm:0]** **[1596812_0001213900-25-082585_ea025461701ex99-2_enlivex.htm:5]** 
- As of June 30, 2025, the company had **$1,892 thousand in cash and cash equivalents** and **$17,615 thousand in short-term interest-bearing deposits**, totaling approximately **$19.5 million** in liquid assets.  **[1596812_0001213900-25-082585_ea025461701ex99-1_enlivex.htm:0]** **[1596812_0001213900-25-082585_ea025461701ex99-2_enlivex.htm:1]** **[1596812_0001213900-25-082585_ea025461701ex99-1_enlivex.htm:9]** 
- The company's management anticipates that existing resources will be sufficient to fund planned operations through the **end of 2026**.  **[1596812_0001213900-25-082585_ea025461701ex99-2_enlivex.htm:1]** **[1596812_0001213900-25-082585_ea025461701ex99-2_enlivex.htm:7]** 
- On **August 18, 2025**, Enlivex announced **positive three-month topline data** from its Phase I/II trial evaluating AllocetraTM in patients with moderate-to-severe knee osteoarthritis.  **[1596812_0001213900-25-082585_ea025461701ex99-2_enlivex.htm:1]** **[1596812_0001213900-25-082585_ea025461701ex99-1_enlivex.htm:9]**

Enlivex Therapeutics (ENLV)